✦ LIBER ✦

276 Promising activity with capecitabine and mitomycin C (MMC) as third line therapy for patients with metastatic colorectal cancer (MCRC) resistant to fluorouracil (5-FU) and irinotecan: results of a phase II study

✍ Scribed by J.L.B. Dickson; S. Rao; M.E. Hill; T.J. Price; A.R. Norman; J. Oates; D. Cunningham

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Capecitabine and mitomycin C as third-li

✍ Chong, G; Dickson, J L B; Cunningham, D; Norman, A R; Rao, S; Hill, M E; Price, 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 89 KB

Results of a Phase II Trial of Cetuximab

✍ Thomas Cartwright; Paul Kuefler; Allen Cohn; William Hyman; Maury Berger; Donald 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 144 KB

A phase II study of irinotecan (CPT-11)

✍ Rosati, G.; Tucci, A.; Rinaldi, A.; Colarusso, D.; Rossi, A.; Pizza, C.; Manzion 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 163 KB

Cetuximab (C225, Erbitux) in combination

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 306 KB

Efficacy and safety of bevacizumab-based

✍ Ducreux, M.; Adenis, A.; Pignon, J.-P.; François, E.; Chauffert, B.; Ichanté, J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 602 KB

6096 POSTER FOLFOXIRI (Irinotecan, Oxali

✍ Fornaro, L.; Loupakis, F.; Lonardi, S.; Masi, G.; Salvatore, L.; Cremolini, C.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB